• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impact of a multidisciplinary workflow on safety and management of patients with heparin-induced thrombocytopenia.多学科工作流程对肝素诱导的血小板减少症患者安全性和管理的影响。
Am J Health Syst Pharm. 2021 Jan 1;78(1):49-59. doi: 10.1093/ajhp/zxaa342.
2
Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol.制定并实施全面的肝素诱导血小板减少症识别与管理方案。
Am J Health Syst Pharm. 2012 Feb 1;69(3):241-8. doi: 10.2146/ajhp110313.
3
The management of suspected heparin-induced thrombocytopenia in US hospitals.美国医院疑似肝素诱导血小板减少症的管理。
Clin Appl Thromb Hemost. 2014 Jan;20(1):68-72. doi: 10.1177/1076029612456732. Epub 2012 Aug 14.
4
Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management.肝素诱导的血小板减少症(HIT):发病率、诊断和管理的综述。
Vasc Med. 2020 Apr;25(2):160-173. doi: 10.1177/1358863X19898253. Epub 2020 Mar 20.
5
Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences.由于肝素诱导的血小板减少症误诊,导致医疗记录中肝素过敏记录不当:频率和后果。
J Thromb Haemost. 2017 Feb;15(2):370-374. doi: 10.1111/jth.13565. Epub 2016 Dec 24.
6
Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory.肝素诱导的血小板减少症:通过住院抗凝药房服务与医院参考实验室之间的合作减少误诊
J Thromb Thrombolysis. 2016 Nov;42(4):471-8. doi: 10.1007/s11239-016-1381-0.
7
Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis.疑似肝素诱导的血小板减少症的管理策略:一项成本效益分析。
Pharmacoeconomics. 2007;25(11):949-61. doi: 10.2165/00019053-200725110-00005.
8
[Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].[疑似肝素诱导的血小板减少症中达那肝素处方的多学科会诊]
Presse Med. 2007 May;36(5 Pt 1):786-93. doi: 10.1016/j.lpm.2006.12.026. Epub 2007 Feb 14.
9
Assessing the impact of a heparin-induced thrombocytopenia protocol on patient management, outcomes and cost.评估肝素诱导的血小板减少症方案对患者管理、结局和成本的影响。
Thromb Haemost. 2012 Nov;108(5):992-8. doi: 10.1160/TH12-05-0289. Epub 2012 Sep 5.
10
Heparin induced thrombocytopenia: diagnosis and management.肝素诱导的血小板减少症:诊断与管理。
J Neurointerv Surg. 2010 Dec;2(4):371-8. doi: 10.1136/jnis.2010.002840. Epub 2010 Jul 23.

引用本文的文献

1
Autoimmune Heparin-Induced Thrombocytopenia.自身免疫性肝素诱导的血小板减少症
J Clin Med. 2023 Nov 3;12(21):6921. doi: 10.3390/jcm12216921.
2
"Autoimmune HIT" antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes.诊断样本中的“自身免疫性血小板减少性紫癜”抗体可能是一种假象,与更严重的结果无关。
Blood Adv. 2023 Aug 22;7(16):4431-4434. doi: 10.1182/bloodadvances.2023009811.

本文引用的文献

1
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.美国血液学会 2018 年静脉血栓栓塞症管理指南:肝素诱导的血小板减少症。
Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489.
2
ASHP Guidelines on Preventing Medication Errors in Hospitals.美国卫生系统药师协会医院预防用药错误指南。
Am J Health Syst Pharm. 2018 Oct 1;75(19):1493-1517. doi: 10.2146/ajhp170811.
3
Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences.由于肝素诱导的血小板减少症误诊,导致医疗记录中肝素过敏记录不当:频率和后果。
J Thromb Haemost. 2017 Feb;15(2):370-374. doi: 10.1111/jth.13565. Epub 2016 Dec 24.
4
Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program.实施止血和抗栓管理计划前后肝素诱导的血小板减少症的治疗
J Thromb Thrombolysis. 2016 Nov;42(4):616-22. doi: 10.1007/s11239-016-1408-6.
5
Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory.肝素诱导的血小板减少症:通过住院抗凝药房服务与医院参考实验室之间的合作减少误诊
J Thromb Thrombolysis. 2016 Nov;42(4):471-8. doi: 10.1007/s11239-016-1381-0.
6
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study.4Ts 评分联合 PF4/H-PaGIA 检测在肝素诱导血小板减少症诊断和管理中的应用:前瞻性队列研究。
Blood. 2015 Jul 30;126(5):597-603. doi: 10.1182/blood-2014-12-618165. Epub 2015 Apr 29.
7
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.肝素诱导的血小板减少症的治疗和预防:抗血栓治疗与血栓预防,第 9 版:美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303.
8
Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparin-induced thrombocytopenia.对疑似肝素诱导的血小板减少症患者4Ts评分的观察者间可靠性进行前瞻性评估。
J Thromb Haemost. 2012 Jan;10(1):151-2. doi: 10.1111/j.1538-7836.2011.04552.x.
9
Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient).肝素诱导的血小板减少症:误区与误解(会给你和你的患者带来麻烦)
Arch Intern Med. 2004 Oct 11;164(18):1961-4. doi: 10.1001/archinte.164.18.1961.
10
The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia.残余肝素对肝素诱导的血小板聚集检测在肝素相关血小板减少症诊断中结果判读的影响。
Thromb Haemost. 1992 Jul 6;68(1):88.

多学科工作流程对肝素诱导的血小板减少症患者安全性和管理的影响。

Impact of a multidisciplinary workflow on safety and management of patients with heparin-induced thrombocytopenia.

机构信息

Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC.

Department of Pharmacy, Emory University Hospital Midtown, Atlanta, GA.

出版信息

Am J Health Syst Pharm. 2021 Jan 1;78(1):49-59. doi: 10.1093/ajhp/zxaa342.

DOI:10.1093/ajhp/zxaa342
PMID:33103184
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7947986/
Abstract

PURPOSE

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin administration. Management strategies are complex and include discontinuing heparin products, initiating alternative anticoagulants, interpreting laboratory test results, documenting heparin allergies, and providing patient education. Medication error reports and a retrospective review conducted at an academic medical center revealed an opportunity for a quality improvement initiative and led to the creation of a multidisciplinary workflow for the management of HIT. In a pre-post study, the impact of the multidisciplinary workflow on the safety and management of HIT was evaluated.

METHODS

The preimplementation group consisted of adult patients tested for suspected HIT from April 4, 2014, through May 31, 2016; the postimplementation group consisted of adult patients tested from November 1, 2016, through October 31, 2018. The primary outcome was the incidence of heparin product administration while HIT testing was ongoing. The secondary outcome was the rate of appropriate heparin allergy documentation.

RESULTS

The incidence of heparin product administration while HIT testing results were pending was significantly reduced, from 54.2% to 20.0% (P < 0.001), after workflow implementation. The rate of appropriate heparin allergy documentation significantly increased, from 95.0% to 100% (P < 0.001).

CONCLUSION

Implementation of a multidisciplinary workflow for the management of HIT significantly reduced the incidence of heparin administration while testing was ongoing and improved the rate of appropriate heparin allergy documentation.

摘要

目的

肝素诱导的血小板减少症(HIT)是肝素给药的严重并发症。管理策略较为复杂,包括停止肝素产品的使用、启动替代抗凝剂、解读实验室检测结果、记录肝素过敏情况并对患者进行教育。在一家学术医疗中心,药物错误报告和回顾性审查揭示了一个进行质量改进的机会,从而促成了 HIT 管理的多学科工作流程的建立。通过一项前后研究,评估了多学科工作流程对 HIT 安全性和管理的影响。

方法

在实施前,纳入 2014 年 4 月 4 日至 2016 年 5 月 31 日期间因疑似 HIT 而接受检测的成年患者;在实施后,纳入 2016 年 11 月 1 日至 2018 年 10 月 31 日期间因疑似 HIT 而接受检测的成年患者。主要结局为在 HIT 检测期间继续使用肝素产品的发生率。次要结局为适当记录肝素过敏情况的比例。

结果

实施工作流程后,在等待 HIT 检测结果时继续使用肝素产品的发生率从 54.2%显著降低至 20.0%(P<0.001)。适当记录肝素过敏情况的比例从 95.0%显著增加至 100%(P<0.001)。

结论

HIT 管理的多学科工作流程的实施显著降低了在等待检测结果时继续使用肝素的发生率,并提高了适当记录肝素过敏情况的比例。